Brokers Issue Forecasts for AMLX FY2026 Earnings

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Amylyx Pharmaceuticals in a report issued on Thursday, November 5th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings of ($1.51) per share for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q4 2026 earnings at ($0.36) EPS, FY2027 earnings at ($1.42) EPS, FY2028 earnings at ($0.99) EPS, FY2029 earnings at $3.06 EPS and FY2030 earnings at $6.13 EPS.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38).

Other analysts also recently issued research reports about the company. Wolfe Research raised Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 17th. Guggenheim upped their price objective on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Robert W. Baird upped their price objective on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 19th. Citigroup increased their target price on Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, October 15th. Finally, Stifel Nicolaus set a $45.00 target price on Amylyx Pharmaceuticals in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $44.14.

Amylyx Pharmaceuticals Stock Up 2.4%

Shares of NASDAQ:AMLX opened at $30.21 on Monday. The company has a market cap of $3.37 billion, a PE ratio of -20.98 and a beta of -0.09. Amylyx Pharmaceuticals has a fifty-two week low of $10.83 and a fifty-two week high of $41.14. The firm has a 50-day simple moving average of $29.91 and a 200 day simple moving average of $20.48.

Institutional Trading of Amylyx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Amylyx Pharmaceuticals during the 2nd quarter worth $158,534,000. Jupiter Topco LLC acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at $94,014,000. Janus Henderson Group PLC increased its holdings in shares of Amylyx Pharmaceuticals by 11.6% during the first quarter. Janus Henderson Group PLC now owns 4,986,073 shares of the company’s stock valued at $69,257,000 after purchasing an additional 520,201 shares during the period. Alyeska Investment Group L.P. bought a new stake in shares of Amylyx Pharmaceuticals during the second quarter valued at about $18,912,000. Finally, Almitas Capital LLC bought a new stake in shares of Amylyx Pharmaceuticals during the second quarter valued at about $17,509,000. Institutional investors own 95.84% of the company’s stock.

Insider Activity

In other news, CFO James Frates sold 10,810 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $32.36, for a total transaction of $349,811.60. Following the sale, the chief financial officer owned 233,625 shares of the company’s stock, valued at approximately $7,560,105. The trade was a 4.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director M Jr sold 30,000 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $27.70, for a total value of $831,000.00. Following the sale, the director directly owned 782,881 shares in the company, valued at approximately $21,685,803.70. This trade represents a 3.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 60,374 shares of company stock worth $1,815,257 over the last ninety days. 10.90% of the stock is owned by company insiders.

Amylyx Pharmaceuticals Company Profile